News

Judo Bio Marks $100M Financing and Welcomes Rajiv Patni as CEO

Judo Bio Marks $100M Financing and Welcomes Rajiv Patni as CEO

Judo Bio Secures Major Financing for Kidney Therapies

Judo Bio, an innovative biotechnology firm dedicated to the development of oligonucleotide medicines specifically for the kidney, has successfully launched with a substantial financing round totaling $100 million. This capital infusion includes both seed financing and Series A funding, showcasing the strong interest from investors in Judo's promising technology. Founded by Atlas Venture and incubated through collaborative efforts, Judo Bio's recent funding round was co-led by Atlas Venture and TCG, with additional contributions from Droia Ventures and several other undisclosed entities.

Revolutionizing Oligonucleotide Delivery to the Kidney

The company's focus revolves around a unique approach to design oligonucleotide therapies capable of targeting the kidney, an organ that presents significant challenges for genetic treatment access. Judo Bio has made remarkable strides, having completed preclinical studies that effectively illustrate receptor-mediated delivery of oligonucleotides to kidney cells. This is achieved using proprietary ligand-siRNA conjugates that can silence multiple target genes, positioning Judo Bio at the forefront of therapeutic advancements.

Moving Forward with Cutting-Edge Technology

The funding gained will be instrumental in propelling Judo Bio's leading ligand-siRNA conjugate into clinical trials, as well as furthering the development of the company's innovative STRIKE (Selectively Targeting RNA Into KidnEy) platform. Among the initial drug programs in development are the megalin-STRIKERs, which leverage the megalin receptor family to direct siRNA therapies to specific kidney cells. This selective targeting can effectively silence mRNA related to solute carrier proteins (SLCs), thereby addressing systemic diseases linked with these proteins.

Experienced Leadership at the Helm

The announcement of Rajiv Patni as Chief Executive Officer marks a significant step for Judo Bio. Dr. Patni brings over 25 years of experience in the pharmaceutical and biotechnology sectors, having previously served as the Chief R&D Officer at Reata Pharmaceuticals. His expertise extends across several biotech companies, where he has facilitated drug approvals and strategic acquisitions. Dr. Patni, in joining Judo Bio, expressed enthusiasm for contributing to the growth and success of this pioneering venture.

Team of Experts Driving Innovation

Judo Bio boasts a leadership team that includes esteemed professionals in the field of oligonucleotide drug development. Notable figures include John Maraganore, Ph.D., who previously served as CEO of Alnylam, commenting on the breakthrough potential of Judo's targeted oligonucleotide medicines. The company’s scientific endeavors are championed by Alfica Sehgal, Ph.D., who has significant contributions to RNA and siRNA therapeutic programs.

In addition to their internal expertise, Judo Bio's advisory board features renowned specialists with extensive backgrounds in kidney-targeted therapeutic development and biotechnology company creation.

Future Prospects and Directions

With the financial backing now secured, Judo Bio is poised to build upon its strong foundation. Dr. Patni stated, "I am humbled to join an outstanding and very supportive leadership team. We aim to develop and nominate new candidates efficiently, focusing on achieving timely proof-of-concept data.” This commitment aligns with the company’s goal of revolutionizing treatment for renal diseases through innovative genetic therapies.

About Judo Bio

Judo Bio is on an ambitious path to overhaul treatment methodologies for a range of systemic and renal diseases through pioneering oligonucleotide medicines. Their STRIKE platform represents a significant leap forward, utilizing a proprietary technique for generating ligand-RNA conjugates that can efficiently achieve gene silencing in targeted kidney cell types. Through an unwavering commitment to scientific excellence and innovation, Judo Bio aims to create transformative therapies. For more information about Judo Bio and its initiatives, interested parties are encouraged to visit their official website.

Frequently Asked Questions

What is Judo Bio focused on developing?

Judo Bio is focused on developing oligonucleotide medicines specifically targeting the kidney to address systemic and renal diseases.

Who has been appointed as the CEO of Judo Bio?

Rajiv Patni, M.D., has been appointed as the Chief Executive Officer of Judo Bio.

What is the STRIKE platform?

The STRIKE (Selectively Targeting RNA Into KidnEy) platform is Judo Bio’s proprietary technology designed for delivering RNA therapeutics to specific kidney cells.

How much funding did Judo Bio secure?

Judo Bio secured $100 million in initial financing, including seed financing and Series A funding.

What are megalin-STRIKERs?

Megalin-STRIKERs are Judo Bio’s initial pipeline programs that utilize megalin receptors for the targeted delivery of siRNA therapeutics to the kidney.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Diaper Affordability: A Hidden Crisis, Taxpayer Burden

Updated Category News Views 6

A Silent Crisis Lurking in Diapers Diapers. We don’t think about them much until we need them, but nearly half of U.S. families are painfully aware of their cost. According to a report from the NDBN Diaper Check 2026, many struggle to meet this basic necessity. This isn't just about keeping babies clean—it's a public health issue with economic ripples Congress can't...

Continue Reading
USFCR Wins 2026 Award for Federal Contracting Services

Updated Category News Views 3

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 3

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 2

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Updated Category News Views 3

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Continue Reading
K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 6

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
OneAscent Welcomes Monica Stoudemire as New CCO

Updated Category News Views 2

New Leadership in Compliance Diving straight into the tumultuous sea of securities compliance, OneAscent's got a fresh captain at the helm. Monica Stoudemire's stepped into the Chief Compliance Officer's shoes with a track record that'd make any investor breathe a sigh of relief. After all, blending two decades of on-the-ground experience with regulatory acumen ain't...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 2

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading
BusyBee AI Revolutionizes Classroom Feedback Efficiency

Updated Category News Views 1

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Continue Reading
SES Sells to AFC Industries: A Strategic M&A Move

Updated Category News Views 0

Nashville's Notable Deal in Industrial Supply On a muggy September day in Nashville, XLCS Partners announced it was at the helm of a noteworthy transaction—the sale of Signature Engineered Solutions (SES) to AFC Industries. Now, this isn't just another corporate shuffle; it's a calculated move in the gritty world of fastening and engineered solutions. The Nitty-Gritty...

Continue Reading

Top 5 Most Recently Viewed Articles

Hedi Slimane's Departure from Celine: A Momentous Shift

Updated Category News Views 71

Hedi Slimane's Departure from Celine: What It Means Fashion designer Hedi Slimane has officially left LVMH's Celine brand, a transition that resonates deeply within the luxury fashion industry. This significant change comes at a time when several prominent designers have shifted their roles, hinting at broader industry turbulence. The New Leadership at Celine In the wake...

Continue Reading
First Capital, Inc. Shows Growth in Quarterly Earnings Report

Updated Category News Views 182

First Capital, Inc. Financial Performance Overview First Capital, Inc. (NASDAQ: FCAP), the entity behind First Harrison Bank, has showcased a strong financial performance in its most recent quarterly earnings report. The company reported a net income of $3.8 million or $1.13 per diluted share for the quarter ending June 30, contrasting sharply with $2.8 million or $0.85...

Continue Reading
Kala Bio Faces Major Setback as Research Hits Snag

Updated Category News Views 187

Understanding Kala Bio's Recent Stock Decline Kala Bio Inc. (NASDAQ: KALA) has experienced a significant drop in its stock price following an announcement about the halted development of an experimental treatment aimed at addressing a specific eye condition. The CHASE Trial Outcomes On a recent Monday, Kala Bio revealed that their CHASE Phase 2b clinical trial for...

Continue Reading
Iron Mountain to Highlight Innovations at Major Conference

Updated Category News Views 163

Iron Mountain Showcases Innovations at Major Conference Iron Mountain Incorporated (NYSE: IRM), recognized for its expertise in information management services, is preparing to make a notable impression at an upcoming financial conference. The company will take part in a fireside chat during the highly anticipated RBC Capital Markets Global Communications Infrastructure...

Continue Reading
Windstar Cruises Unveils Unique Dining on Star Seeker

Updated Category News Views 160

Windstar Cruises Introduces Dining Venues on Star Seeker Windstar Cruises is excited to share insights into the interior design of the dining and lounge spaces on its upcoming yacht, Star Seeker. This vessel is set to redefine cruise experiences with its innovative approach to dining and social interaction. Amphora Restaurant: A Culinary Delight At the forefront of Star...

Continue Reading